No capital gains tax on Sanofi for Shantha deal: HC

Feb 16 2013, 09:27 IST
Comments 0
SummaryDeal protected under DTAA even after retrospective amendments

In what showed the limitation of Indias recent retrospective amendments in tax laws concerning indirect transfers abroad of Indian assets, the Andhra Pradesh High Court on Friday ruled that notwithstanding the bolstered law, French drug multinational Sanofi need not pay capital gains tax in India for its acquisition of Hyderabad-based vaccine manufacturer Shantha Biotech in 2009.

The court said Sanofi, which is liable to pay tax in France for the Rs 3,800-crore deal, wont have to pay tax in India also thanks to the protection afforded by the India-French double taxation avoidance agreement (DTAA). Indian tax authorities had asked Sanofi to pay over Rs 650 crore as capital gains tax.

Sanofi Aventis, as it was then known, had bought out Shantha Biotechnics through acquisition of ShanH, which held a majority stake in Shantha. ShanH, the French subsidiary of Merieux Alliance, had earlier bought out Shantha in November 2008. The court held that ShanH was a company with commercial substance and so the deal was eligible for treaty protection.

The government is likely to challenge the order in the Supreme Court.

The HC ruling have positive implications for at least a couple of similar cross-border deals where the buyers face Indian tax demands, including British brewing giant SAB Miller, which bought out Fosters Group for $10.2 billion in September 2011. SAB Miller claims that the transaction enjoyed protection of the India-Australia DTAA.

Rajiv Chug, partner, direct tax, Ernst & Young said: As long as the entity in the treaty-partner country has commercial substance and is not a sham entity or mere nominee, the treaty protection is bound to be there.

However, Fridays court ruling will have little effect on the high-profile Vodafone case, as the relevant deal did not enjoy any duty protection.

The government is apparently having a rethink on the retrospective amendments of Section 9 of the Income Tax Act meant to tax deals similar to Vodafone involving offshore transfer of shares, which have derived value substantially from assets located in India. Separately, informal talks are on with Vodafone on reaching an amicable settlement over the Rs 11,000-crore tax demand raised. As the law stands today, the amendment covers all such offshore transactions.

The Parthasarathi Shome committee has voted against retrospective applicability of the law on indirect transfer of assets brought in through the Finance Act, 2012, but proposed some clarifications that would substantially reduce the irritant nature of the law, regardless of whether past cases remain within its domain.

It said the government should apply the provision only to the taxpayer who earned capital gains (the seller) and suggested that no taxpayer in such cases be asked to pay interest and penalty on the tax computed.

The Sanofi case came up for hearing on Friday and law firm Economic Laws Practice appeared for the petitioners. Rohit Jain, partner, Economic Laws Practice, said: This is a good judgment and sets out the law as applicable by the Indo-French treaty which continues even after retrospective amendments.

According to the counsel, the transaction of the sale of shares of ShanH by the French company Sanofi is not a design for tax avoidance. The transaction is chargeable to tax in France, in terms of the provisions of the DTAA, and retrospective amendments to the Income Tax Act have no impact on the DTAA.

Earlier also, the Andhra Pradesh High Court had dismissed the plea of the tax authorities against the Authority for Advanced Rulings (AAR) admission of Sanofis application regarding the Shantha Biotech deal.

Ads by Google

More from Business

Reader´s Comments
| Post a Comment
Please Wait while comments are loading...